STOCK TITAN

Alcon (ALC) Stock Price, News & Analysis

ALC NYSE
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
2 252 sessions, November 19, 2025 to November 19, 2026
Largest daily move
-12.1% close of May 6, 2026
1-year change
-1.2% closing prices, November 19, 2025 to November 19, 2026
1-month change
+12.7% closing prices, October 19, 2026 to November 19, 2026

Company Description

Alcon Inc. (ALC) is an ophthalmic goods manufacturer and global eye care company whose shares trade on both the SIX Swiss Exchange and the New York Stock Exchange under the symbol ALC. According to company disclosures, Alcon describes itself as the global leader in eye care, with a heritage spanning more than 75 years. The company focuses on products and technologies that enhance sight and address a range of eye conditions.

Alcon reports that it offers the broadest portfolio of products to enhance sight and improve people’s lives, organized around two main areas: Surgical and Vision Care. Its Surgical and Vision Care products are used by patients living with conditions such as cataracts, glaucoma, retinal diseases and refractive errors. These offerings are used by eye care professionals in many markets and reach a large patient base worldwide.

Business Segments and Operations

Alcon’s activities are structured into two primary segments. The Surgical segment includes products and equipment used in ophthalmic surgery. The Vision Care segment covers products used in everyday eye care and vision correction. Company materials state that Alcon’s Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year, reflecting the geographic breadth of its operations and distribution.

Within these segments, Alcon highlights a portfolio that spans a range of eye care needs, from surgical interventions for cataracts and retinal conditions to products addressing refractive errors and other ocular health issues. The company emphasizes that its offerings are designed to enhance outcomes for eye care disorders and help patients see more clearly.

Heritage and Corporate Profile

Alcon notes that it has a heritage in eye care that extends over 75 years. Over this period, the company has developed and expanded its product portfolio and global footprint. Public information indicates that Alcon operates as a foreign private issuer for U.S. securities law purposes and files reports on Form 20-F and Form 6-K with the U.S. Securities and Exchange Commission. Its principal executive offices are located in Fribourg, Switzerland.

Alcon’s disclosures also reference a large global workforce. The company states that more than 25,000 associates work to enhance quality of life through its products, partnerships with eye care professionals, and programs that aim to advance access to quality eye care.

Eye Care Focus and Therapeutic Areas

Alcon’s stated mission is to help people see brilliantly. The company focuses on eye conditions that significantly affect vision and quality of life. These include cataracts, where clouding of the eye’s natural lens impairs sight; glaucoma, a group of conditions associated with damage to the optic nerve; retinal diseases, which affect the light-sensitive tissue at the back of the eye; and refractive errors, such as myopia and hyperopia, where the eye does not bend light correctly.

Through its Surgical segment, Alcon provides products used in procedures that address many of these conditions. Through its Vision Care segment, it offers products used in daily life to correct or manage refractive errors and support ocular health. The company positions this combination of surgical and non-surgical offerings as a way to serve patients across the continuum of eye care.

Global Reach and Market Presence

Alcon reports that its products are used in more than 140 countries, indicating a broad international presence. This global reach is supported by relationships with eye care professionals and by programs that seek to expand access to eye care services. The company’s disclosures emphasize partnerships with Eye Care Professionals and initiatives that advance access to quality eye care as part of its operating approach.

As a publicly traded company on both SIX and NYSE, Alcon is subject to regulatory oversight in multiple jurisdictions and provides periodic updates to investors through press releases, interim financial reports, and other filings. These materials often discuss developments in its Surgical and Vision Care franchises and broader corporate strategy.

Corporate Actions and Strategic Direction

Alcon’s recent communications include information about strategic transactions and corporate decisions. For example, a company press release dated January 6, 2026, referenced in a Form 6-K filing, states that Alcon terminated a definitive merger agreement with STAAR Surgical Company that had been announced in August 2025. In connection with that announcement, Alcon indicated that its refractive strategy remained unchanged and highlighted its focus on a wavelight plus offering for LASIK procedures.

The same press release noted that Alcon anticipated global launches of more than 10 major products in both its surgical and vision care franchises over the course of the year, describing these as innovations that advance outcomes for eye care disorders. This illustrates how Alcon uses acquisitions, product development and portfolio expansion to support its position in the ophthalmic goods manufacturing and broader eye care markets.

Regulatory Filings and Investor Communications

As a foreign issuer in the United States, Alcon submits current reports on Form 6-K to furnish press releases and interim financial information. Recent 6-K filings reference press releases and an interim financial report, as well as detailed segment disclosures that distinguish between its Surgical and Vision Care segments and further break down categories such as implantables, consumables, equipment, contact lenses and ocular health.

These filings provide insight into how Alcon organizes its business and reports performance across different product categories and geographic areas, including the United States and international regions. Investors and analysts use this information to understand the company’s segment structure and the relative contribution of different parts of the business.

Alcon Stock (ALC) for Investors

For investors researching ALC stock, Alcon represents an established participant in the ophthalmic goods manufacturing sector and the broader eye care industry. The company’s disclosures emphasize a long heritage, a broad product portfolio across Surgical and Vision Care, and a large global patient reach. Its dual listing on SIX and NYSE, along with regular SEC filings, provides multiple channels for accessing information about its operations, strategy and financial reporting framework.

Because Alcon focuses on eye care, developments in its product pipeline, regulatory environment, and strategic transactions can be important considerations for those evaluating ALC shares. Company press releases and Form 6-K submissions are key sources for understanding these developments over time.

Stock Performance

$74.50
-1.01%
-0.76
Last updated: at
-1.2%
Performance 1 year
$35.8B

Alcon (ALC) closed at $74.50 on November 19, 2026. Over the past 12 months, the price has lost 1.2%.

See what a $1,000 investment in ALC would be worth today

Average down calculator for ALC

ALC Metrics & Rankings

Price returns through November 19, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Financial Highlights

Alcon generated $10.4B in revenue in FY2025, retaining a 55.2% gross margin, operating income reached $1.4B (13.1% operating margin), and net income was $980.0M, reflecting a 9.4% net profit margin. Diluted earnings per share stood at $1.98. The company generated $2.3B in operating cash flow. The current ratio was 2.12, measuring current assets divided by current liabilities.

$10.4B
Revenue (FY2025)
$980.0M
Net Income (FY2025)
$2.3B
Operating Cash Flow

Upcoming Events

DEC
19
December 19, 2026 Corporate

Shareholder vote on sale

STAAR special shareholder meeting to vote on proposed sale to Alcon; vote delayed to Dec 19

Alcon has 1 upcoming scheduled event. The next event, "Shareholder vote on sale", is scheduled for December 19, 2026 (in 30 days). Investors can track these dates to stay informed about potential catalysts that may affect the ALC stock price.

Short Interest History

Last 12 Months

Short interest in Alcon (ALC) currently stands at 18.4 million shares, down 5.7% from the previous reporting period, representing 3.8% of the float. Since November 2025, short interest has increased by 199.2%.

Days to Cover History

Last 12 Months

Days to cover for Alcon (ALC) currently stands at 12.6 days, up 16.4% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has increased by 285.4%. Across the settlements charted above, it has ranged from 2.0 to 12.6 days.

ALC Company Profile & Sector Positioning

Alcon (ALC) operates in the Medical Instruments & Supplies industry within the broader Healthcare sector and is listed on the NYSE. Among dividend-paying stocks, ALC ranks #1,940 by dividend yield.

Investors comparing ALC often look at related companies in the same sector, including ResMed Inc. (RMD), West Pharmaceutical Services, Inc. (WST), Medline (MDLN), Becton, Dickinson and Co. (BDX), and The Cooper Companies, Inc. (COO). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate ALC's relative position within its industry.

Frequently Asked Questions

The current stock price of Alcon (ALC) is $74.50 as of November 19, 2026.

The market cap of Alcon (ALC) is approximately $35.8B. Learn more about what market capitalization means .

The FY2025 revenue of Alcon (ALC) is $10.4B, from its most recent completed fiscal year.

The FY2025 net income of Alcon (ALC) is $980.0M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Alcon (ALC) is $1.98 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Alcon (ALC) is $2.3B for FY2025, its most recent completed fiscal year. Learn about cash flow.

The net profit margin of Alcon (ALC) is 9.4% for FY2025, its most recent completed fiscal year. Learn about profit margins.

The operating profit margin of Alcon (ALC) is 13.1% for FY2025, its most recent completed fiscal year. Learn about operating margins.

The gross profit margin of Alcon (ALC) is 55.2% for FY2025, its most recent completed fiscal year. Learn about gross margins.

The current ratio of Alcon (ALC), current assets divided by current liabilities, was 2.12 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The gross profit of Alcon (ALC) is $5.7B for FY2025, its most recent completed fiscal year.

The operating income of Alcon (ALC) is $1.4B for FY2025, its most recent completed fiscal year. Learn about operating income.

Alcon Inc. focuses on eye care, offering Surgical and Vision Care products that enhance sight and address conditions such as cataracts, glaucoma, retinal diseases and refractive errors. The company describes itself as the global leader in eye care with a broad portfolio of products used by patients and eye care professionals worldwide.

Alcon reports two primary business segments: Surgical and Vision Care. The Surgical segment includes products and technologies used in ophthalmic surgery, while the Vision Care segment includes products used in daily eye care and vision correction, as well as ocular health offerings.

Alcon’s principal executive offices are in Fribourg, Switzerland, as disclosed in its Form 6-K filings. The company’s shares trade on the SIX Swiss Exchange and the New York Stock Exchange under the ticker symbol ALC.

According to company materials, Alcon’s Surgical and Vision Care products are used by people living with cataracts, glaucoma, retinal diseases and refractive errors. These conditions can significantly affect vision, and Alcon’s portfolio is designed to improve sight and quality of life for affected patients.

Alcon states that its Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year. This reflects a broad international footprint supported by relationships with eye care professionals and programs that promote access to quality eye care.

Alcon describes its heritage in eye care as spanning more than 75 years. Over this period, the company has built a wide range of Surgical and Vision Care products and expanded its presence across many countries.

Alcon states that it helps people see brilliantly. This mission is reflected in its focus on products that enhance sight, its emphasis on improving people’s lives, and its partnerships with Eye Care Professionals and programs that advance access to quality eye care.

Company materials indicate that Alcon has more than 25,000 associates. These associates are described as working to enhance quality of life through the company’s products, professional partnerships and access-to-care programs.

In a press release dated January 6, 2026, furnished on Form 6-K, Alcon announced that it had terminated its definitive merger agreement with STAAR Surgical Company that was originally announced in August 2025. In the same communication, Alcon stated that its refractive strategy was unchanged and highlighted a focus on its wavelight plus offering for LASIK.

As a foreign private issuer, Alcon files annual reports on Form 20-F and current reports on Form 6-K with the U.S. Securities and Exchange Commission. These filings often include press releases, interim financial reports and segment information, providing investors with updates on the company’s operations and strategy.